Form 8-K - Current report:
SEC Accession No. 0001564590-21-043986
Filing Date
2021-08-12
Accepted
2021-08-12 16:16:32
Documents
14
Period of Report
2021-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fdmt-8k_20210812.htm   iXBRL 8-K 37717
2 EX-99.1 fdmt-ex991_6.htm EX-99.1 156995
3 GRAPHIC gdewbaw3cn1i000001.jpg GRAPHIC 12469
  Complete submission text file 0001564590-21-043986.txt   352263

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA fdmt-20210812.xsd EX-101.SCH 5745
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE fdmt-20210812_lab.xml EX-101.LAB 19322
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fdmt-20210812_pre.xml EX-101.PRE 11532
7 EXTRACTED XBRL INSTANCE DOCUMENT fdmt-8k_20210812_htm.xml XML 3560
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics Inc. (Filer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 211167781
SIC: 2836 Biological Products, (No Diagnostic Substances)